This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Fenretinide, 4-HPR, 4HPR, 4 HPR
CerRx's fenretinide is an emulsion formulation of fenretinide (4-HPR), a synthetic retinoic acid derivative.
Sphingolipids are critical components of cell membranes. The key building blocks in the formation of the many kinds of sphingolipids are ceramides which exist in several forms, including dihydroceramides. Fenretinide increases toxic dihydroceramide in cancer cells by stimulating their de novo synthesis while simultaneously blocking their conversion to desaturated ceramides. Fenretinide does not cause dihydroceramide to build up in normal cells. Therefore, fenretinide is not toxic to normal cells and is better-tolerated in patients than many other anticancer agents.
Fenretinide (CerRx) News
Scrip Sirion Therapeutics Inc.
Additional information available to subscribers only: